Tuesday, 02 January 2024 12:17 GMT

Global Synthetic Antibody Library Market Report 2026: Size And Forecast To 2030 Capitalize On 12% CAGR And AI Design With Charles River, Twist Bioscience, Genscript And Abcellera


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.

Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- "Synthetic Antibody Library Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research and development, and wider adoption of advanced antibody discovery technologies. The market is projected to increase from $1.63 billion in 2025 to $1.82 billion in 2026, representing a compound annual growth rate (CAGR) of 11.7%.

Historical market growth has been driven by the increasing use of phage and yeast display technologies, expanding academic research activity, and the growing application of synthetic antibodies in diagnostics. Pharmaceutical and biotechnology organizations are using synthetic antibody libraries to streamline candidate identification, improve binding specificity, and support the development of biologic drugs across multiple therapeutic areas.

Looking ahead, the synthetic antibody library market is forecast to reach $2.86 billion by 2030, expanding at a CAGR of 12%. Growth during the forecast period is expected to be supported by the integration of artificial intelligence in antibody design, increasing demand for messenger ribonucleic acid (mRNA) display libraries, personalized medicine initiatives, investment in high-diversity libraries, and the expansion of contract research organizations.

Prominent synthetic antibody library market trends include high-throughput antibody screening, automated library construction, next-generation sequencing integration, computational antibody design, and customizable antibody libraries. These technologies are helping research teams evaluate larger numbers of candidates, improve antibody optimization, and reduce the time required to advance promising molecules into preclinical and clinical development.

The increasing demand for targeted therapeutics is a key factor driving synthetic antibody library market growth. Adoption continues to rise amid greater investment in precision medicine and biologic drug development, particularly in oncology and immune disorders. Synthetic antibody libraries provide a scalable platform for discovering highly specific antibodies that bind to disease-associated molecular targets, supporting the development of more accurate and effective treatment candidates.

Clinical research activity further demonstrates the need for advanced antibody discovery capabilities. According to IQVIA's Global Oncology Trends 2024 report, more than 2,000 new oncology clinical trials were launched in 2023. These trials placed significant emphasis on innovative treatment modalities, including cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies. Continued investment in these areas is expected to strengthen demand for synthetic antibody discovery and optimization services.

Innovation within the market is also focused on mammalian-display-based synthetic antibody discovery platforms. In December 2025, Fusion Antibodies plc launched the OptiMAL Human Antibody Discovery platform, combining its proprietary naive synthetic antibody library with mammalian display selection. The platform is designed to accelerate the identification of fully human, high-affinity antibodies while improving native folding, post-translational modifications, binding specificity, and functional relevance. By reducing the need for downstream humanization, the technology may shorten biologic development timelines and lower associated costs.

Strategic acquisitions are further reshaping the competitive environment. In September 2024, France-based Valerio Therapeutics S.A. acquired Emglev Therapeutics for an undisclosed amount. The acquisition enables Valerio Therapeutics to integrate Emglev's fully synthetic single-domain antibody platform into its discovery pipeline, supporting the development of next-generation immunotherapies across multiple therapeutic areas.

North America was the largest region in the synthetic antibody library market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

Markets Covered:
1) By Library Type: Phage Display Libraries; Yeast Display Libraries; Ribosome Display Libraries; Messenger Ribonucleic Acid (mRNA) Display Libraries; Other Library Types
2) By Application: Therapeutic Development; Diagnostic Development; Research and Development; Other Applications
3) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End-Users
Subsegments:
1) By Phage Display Libraries: Filamentous Phage Display Libraries; T7 Phage Display Libraries; Lambda Phage Display Libraries; Hybrid Phage Display Libraries
2) By Yeast Display Libraries: Saccharomyces Cerevisiae Yeast Display Libraries; Pichia Pastoris Yeast Display Libraries; Surface-Displayed Yeast Libraries; Secreted Yeast Display Libraries
3) By Ribosome Display Libraries: In Vitro Ribosome Display Libraries; Cell-Free Ribosome Display Libraries; High-Diversity Ribosome Display Libraries; Functional Ribosome Display Libraries
4) By Messenger Ribonucleic Acid (mRNA) Display Libraries: In Vitro Messenger Ribonucleic Acid (mRNA) Display Libraries; Peptide-Messenger Ribonucleic Acid (mRNA) Fusion Libraries; Protein-Messenger Ribonucleic Acid (mRNA) Fusion Libraries; High-Throughput Messenger Ribonucleic Acid (mRNA) Display Libraries
5) By Other Library Types: Phage Display Library; Yeast Display Library; Ribosome Display Library; mRNA Display Library; Bacterial Display Library; Mammalian Cell Display Library; Synthetic Peptide Library; Combinatorial Antibody Library; Single Domain Antibody Library; Nanobody Library
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:

Report Attribute Details
No. of Pages 250
Forecast Period 2026 - 2030
Estimated Market Value (USD) in 2026 $1.82 Billion
Forecasted Market Value (USD) by 2030 $2.86 Billion
Compound Annual Growth Rate 12.0%
Regions Covered Global


Companies Featured
The companies featured in this Synthetic Antibody Library market report include:

  • Charles River Laboratories International Inc.
  • Bio-Rad Laboratories Inc.
  • Aragen Life Sciences Pvt. Ltd.
  • Twist Bioscience Corporation
  • GenScript Biotech Corporation
  • Abzena plc
  • Harbour BioMed
  • Alector Inc.
  • IRBM S.p.A.
  • AbCellera Biologics Inc.
  • Adimab LLC
  • Creative Biolabs Inc.
  • ImmunoPrecise Antibodies Ltd.
  • Eurofins Discovery Services Luxembourg Holding S.A.
  • Isogenica Ltd.
  • Ablexis LLC
  • AbDesign Labs LLC
  • Abwiz Bio Inc.
  • Dynegene Inc.
  • Hybrigenics Services SAS
  • ProSci Incorporated.

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN12102026004107003653ID1111795484



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story